Fig. 1

Management of thrombotic risk in patients with diabetes and co-morbidities. All studies listed included patients with diabetes. ^aOnly recommended for patients with prior MI who have tolerated DAPT for 1 year. ^bRivaroxaban is contraindicated in patients with CrCl < 15 mL/min. ^cPost-peripheral revascularization. Published after the latest guideline recommendation. Guidelines recommend rivaroxaban 2.5 mg bid plus aspirin for patients with symptomatic PAD at high risk of ischaemic events. AF, atrial fibrillation; ATT, Antithrombotic Triallists’ Collaboration; bid, twice daily; CAD, coronary artery disease; CKD, chronic kidney disease; CrCl, creatinine clearance; CV, cardiovascular; DAPT, dual antiplatelet therapy; DPI, dual pathway inhibition; GLP-1, glucagon-like peptide-1; NOAC, non-vitamin K antagonist oral anticoagulant; PAD, peripheral artery disease; PCSK9, proprotein convertase subtilisin/kexin type 9; RAAS, renin–angiotensin–aldosterone system; SAPT, single antiplatelet therapy; SGLT2, sodium-glucose co-transporter-2